140.22
前日終値:
$143.53
開ける:
$144.25
24時間の取引高:
958.27K
Relative Volume:
1.48
時価総額:
$8.52B
収益:
$3.99B
当期純損益:
$463.16M
株価収益率:
19.75
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
+2.58%
1か月 パフォーマンス:
+14.96%
6か月 パフォーマンス:
+28.27%
1年 パフォーマンス:
+17.98%
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
名前
Jazz Pharmaceuticals Plc
セクター
電話
353-1-634-7800
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
JAZZ
Jazz Pharmaceuticals Plc
|
140.22 | 8.52B | 3.99B | 463.16M | 1.10B | 7.10 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-26 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2025-02-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-12-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-06-05 | 開始されました | Goldman | Buy |
2024-01-03 | 開始されました | Robert W. Baird | Outperform |
2023-11-27 | ダウングレード | UBS | Buy → Neutral |
2023-09-29 | 開始されました | Raymond James | Mkt Perform |
2023-06-12 | 再開されました | Wells Fargo | Equal Weight |
2022-12-09 | アップグレード | Goldman | Neutral → Buy |
2022-06-14 | 開始されました | UBS | Buy |
2022-04-06 | ダウングレード | Goldman | Buy → Neutral |
2021-11-19 | 再開されました | Goldman | Buy |
2021-10-07 | 再開されました | Jefferies | Buy |
2021-10-05 | 開始されました | Citigroup | Buy |
2021-09-23 | 開始されました | Needham | Buy |
2021-05-19 | 再開されました | JP Morgan | Overweight |
2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
2021-02-03 | アップグレード | Piper Sandler | Neutral → Overweight |
2021-01-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-12-16 | 開始されました | UBS | Buy |
2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-09 | 繰り返されました | H.C. Wainwright | Buy |
2020-09-14 | ダウングレード | Goldman | Neutral → Sell |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-07-28 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-07-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-04-06 | 開始されました | Jefferies | Buy |
2020-03-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
2020-01-08 | 開始されました | Goldman | Neutral |
2019-08-21 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2019-06-11 | 開始されました | Barclays | Overweight |
2019-03-20 | 開始されました | SunTrust | Buy |
2018-12-14 | 開始されました | Wolfe Research | Peer Perform |
2018-11-08 | 繰り返されました | B. Riley FBR | Buy |
2018-08-08 | 繰り返されました | Stifel | Buy |
2018-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2018-03-23 | 繰り返されました | H.C. Wainwright | Neutral |
2018-03-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース
Jazz Pharmaceuticals EVP Neena Patil sells shares worth $550,506 - Investing.com
Jazz Pharmaceuticals plc (JAZZ): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy? - Nasdaq
Truist Financial Corp Has $3.52 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2025 Earnings Guidance - MarketBeat
Needham & Company LLC Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $210.00 - MarketBeat
Jazz downgraded to neutral by Cantor over business strategy - MSN
Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Quarterly Earnings Results - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 52-Week HighShould You Buy? - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat
Principal Financial Group Inc. Decreases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance Australia
International Markets and Jazz (JAZZ): A Deep Dive for Investors - Nasdaq
Jazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus.com
Investor Network: Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
New York State Common Retirement Fund Has $6.68 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Neutral - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Overweight Rating from Piper Sandler - MarketBeat
Royal Bank of Canada Cuts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $178.00 - MarketBeat
Jazz Earnings: Strong Uptake of Xywav and Epidiolex Drive Sales; Shares Undervalued - Morningstar
Kovack Advisors Inc. Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab (JAZZ) - Seeking Alpha
Strong Uptake of Xywav and Epidiolex Drive Growth for Jazz Pharmaceuticals - Morningstar
RBC Capital cuts Jazz Pharmaceuticals stock target to $178 By Investing.com - Investing.com UK
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Nasdaq
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations - MSN
Needham lifts Jazz Pharmaceuticals stock target to $210 By Investing.com - Investing.com UK
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2024 Earnings Call Transcript - Insider Monkey
Jazz Pharmaceuticals plc SEC 10-K Report - TradingView
RBC Trims Price Target on Jazz Pharmaceuticals to $178 From $179, Keeps Outperform Rating - Marketscreener.com
Despite the downward trend in earnings at Jazz Pharmaceuticals (NASDAQ:JAZZ) the stock advances 3.2%, bringing five-year gains to 21% - Yahoo Finance
Jazz: Q4 Earnings Snapshot - The Wilton Bulletin
Jazz Pharmaceuticals PLC (JAZZ) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 4,011 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals PLC reports results for the quarter ended December 31Earnings Summary - TradingView
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Jazz Pharmaceuticals Q4 2024 beats EPS forecasts - Investing.com
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales - Yahoo Finance
Jazz Pharmaceuticals Q4 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Issued - Marketscreener.com
Jazz: Q4 Earnings Snapshot -February 25, 2025 at 04:44 pm EST - Marketscreener.com
Jazz Pharmaceuticals reports strong Q4, but shares slip on muted 2025 outlook - Investing.com India
Jazz Pharmaceuticals 8-K Filing Analysis - TradingView
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance - PR Newswire
Jazz Pharmaceuticals stock hits 52-week high of $139 By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
First Week of April 17th Options Trading For Jazz Pharmaceuticals - Nasdaq
Jazz Pharmaceuticals Plc (JAZZ) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):